Acute Lower Limb Ischaemia and Diabetes in a Patient Treated with Anti-PD1 Monoclonal Antibody for Metastatic Melanoma

Acta Derm Venereol. 2017 Mar 10;97(3):408-409. doi: 10.2340/00015555-2504.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Aged
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Anticoagulants / therapeutic use
  • Antineoplastic Agents / adverse effects*
  • Arterial Occlusive Diseases / chemically induced*
  • Arterial Occlusive Diseases / diagnosis
  • Arterial Occlusive Diseases / therapy
  • Computed Tomography Angiography
  • Diabetes Mellitus / blood
  • Diabetes Mellitus / chemically induced*
  • Diabetes Mellitus / diagnosis
  • Diabetes Mellitus / drug therapy
  • Embolectomy / methods
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Insulin / therapeutic use
  • Ischemia / chemically induced*
  • Ischemia / diagnosis
  • Ischemia / therapy
  • Lower Extremity / blood supply*
  • Male
  • Melanoma / drug therapy*
  • Melanoma / immunology
  • Melanoma / secondary
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Programmed Cell Death 1 Receptor / immunology
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / immunology
  • Skin Neoplasms / pathology
  • Thrombosis / chemically induced*
  • Thrombosis / diagnosis
  • Thrombosis / therapy
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Anticoagulants
  • Antineoplastic Agents
  • Hypoglycemic Agents
  • Insulin
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • pembrolizumab